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osting by EAbstract Recent studies have suggested that polymorphism of the beta-2 adrenergic receptor
(b2AR) gene at codon 16 affect an individual’s airway responsiveness. This study aimed to evaluate
the association between beta-2 adrenoreceptor genotypes at position 16 and asthma severity among
59 school-aged children. They were divided into two groups: control group including 19 healthy
children and 40 asthmatic children as the study group. The study group was also divided into 20
mild asthmatic children and the remaining 20 patients suffered from severe asthma. Blood samples
were collected from Chest Department, Pediatrics Hospital, Ain Shams University, from February
2008 to March 2009. Molecular analysis was performed at Science Faculty, Ain Shams University,
Cairo, Egypt. Venous blood sample were collected and genotyping of b2AR gene polymorphism at
position 16 was identiﬁed by polymerase chain reaction–restriction fragment length polymorphism
analysis, using the NcoI restriction enzyme. We found a highly statistically signiﬁcant difference of
polymorphisms’ distribution of b2AR gene at codon 16 among asthmatic patients and control sub-
jects (v2 = 11.904; P= 0.0026), also among severe asthmatics and mild/moderate asthmaticsrtment of Zoology, Faculty of
, Ain Shams University, Cairo
hams.edu.eg (M.S. Salama),
en_asem@yahoo.com (N.A.
. Hamad).
y. Production and hosting by
Shams University.
lsevier
152 M.S. Salama et al.(v2 = 10.108; P = 0.0064). There was a strong association of heterozygous Arg16Gly of b2AR with
severe asthmatics rather than that in control subjects (70% vs. 5.3%, P< 0.001), with odd ratio
(OR) 42 (95% conﬁdence interval (CI): 4.520–390.297), the highest OR in heterozygous Arg16Gly
(42) suggests a dominant mode of action of the heterozygous Arg16Gly in development of asthma
severity. So, we concluded that heterozygous Arg16Gly of b2AR gene appeared to be an important
genetic factor in the expression of asthma severity.
 2011 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Asthma is a complex genetic disorder that is characterized by
airway inﬂammation and reversible airﬂow obstruction [1].
Asthma prevalence has increased very considerably in recent
decades such that it is now one of the commonest chronic dis-
orders in the world. Asthma prevalence increased signiﬁcantly,
especially in developed countries, and particularly in children.
What caused this increase is currently unknown [2]. Approxi-
mately 300 million people worldwide currently have asthma,
and its prevalence increases by 50% every decade. In North
America, 10% of the population has asthma. The increasing
number of hospital admissions for asthma, which are most
pronounced in young children, reﬂect an increase in severe
asthma and poor disease management. Worldwide, approxi-
mately 180,000 deaths annually are attributable to asthma
[3–5].
Recent study was performed in Cairo, Egypt to ascertain
the prevalence of asthma among children. It revealed that
the overall prevalence of wheezing in the last year was
14.7% and of physician-diagnosed asthma was 9.4% [6].
Beta-2 adrenergic receptors are iniquitous throughout the
human body and are classiﬁed into three distinct subtypes
(b1, b2, and b3) on the basis of their function, agonist-binding
patterns, and genetics. The b3-receptor is found primarily in
adipocytes but is also present in pulmonary endothelial cells.
The proposed b4-receptor appears to be a conformational state
of b1-receptor in myocardial cells. Neither the b3 or b4 recep-
tors have been linked with regulation of ion transport in epi-
thelial cells [7].
The b2-adrenergic receptor is a 1200-bp, single-copy,
intronless gene that encodes a 413-amino acid protein with a
molecular mass of approximately 46.5 kD. The b2-receptor is
a prototypical G protein-coupled receptor (GPCR) with se-
ven-transmembrane domains, an extracellular amino terminus,
an intracellular carboxyl terminus, three interconnecting extra-
cellular loops, and three intracellular loops [8–12].
The b2AR is present in high numbers in the bronchial
smooth muscle, bronchial epithelium and in endothelial cells.
Furthermore, this receptor is present in relatively high num-
bers in peripheral blood vascular smooth muscle, and to a les-
ser extent in the heart [13].
The gene that encodes the b2AR is one of the most studied
candidate genes in asthma. It is situated on the long arm of
chromosome 5 (5q32-q34) [14]. For the gene encoding the b2
adrenergic receptor, several polymorphisms have been de-
scribed in particular at codons 16 Arginine/Glycine and 27
Glutamine/Glutamic acid which alter the receptor function
in vitro [15,16]. The current study will focus on the polymor-
phism of b2 adrenergic receptor gene (b2AR) at codon 16 that
due to preliminary studies which have suggested that b2 adren-
ergic receptor polymorphism is known to be functionallyrelevant and also disease-modifying in subjects with asthma.
Also, it will assess the relation between certain forms of asthma
severity and polymorphism of b2 adrenergic receptor gene.
2. Patients and methods
2.1. Patients
Fifty-nine unrelated children were included in this study. They
were divided into two groups:
Group I (study group): This group included 40 asthmatic
children. Their age ranged between 2 and 12 years. Thorough
history and physical examination were done to exclude other
common conditions that mimic asthma. Participants met stan-
dard criteria for a diagnosis of asthma. They were classiﬁed as
having severe (20 child) or mild to moderate asthma (20)
according to criteria developed by National Institutes of
Health/NHLBI SARP based on American Thoracic Society
Consensus Panel report [17].
Group II (control group): This group included 19 healthy
children of matched age and sex to the study group.
2.2. Methods
Molecular studies were carried out for 59 cases; using a poly-
merase chain reaction (PCR) followed by restriction fragment
length polymorphism (RFLP) to detect the polymorphisms of
b2AR gene at codon 16.
Venous blood samples were collected into sterile EDTA
tubes and stored at 20 C until used. Genomic DNA was iso-
lated from blood samples by using EZ-10 spin column DNA
kit (Biotechnology INC., Canada) to detect the Arg16Gly
polymorphism. DNA was analyzed with speciﬁc-PCR tech-
nique according to the method described by Reihsaus et al.
[18].
The nucleotide sequences of the forward and reverse primer
used for PCR are: 5-CCTTCTTGCTGGCAGCCCATC-3 and
5-GGAAGTCCAAAACTCGCACCA-3.
The ampliﬁcation was reformed by including the reaction
mix for 35 cycles in a thermocycler. Each cycle consisted of
denaturation of DNA at 94 C for 30 s followed by annealing
at 58 C for 30 s and extension at 72 C for 30 s with initial
delay for 2 min at 94 C at the beginning of the ﬁrst cycle
and 10 min delay at 72 C at the end of the last cycle. Ampli-
ﬁed products were stored at 20 C.
The ampliﬁed product by PCR was separated on 1.5% aga-
rose at 100 V for an hour to run alongwith the ladderDNA.The
PCR products were visualized on ultraviolet transilluminator,
and then photographed by using digital camera (Canon, Power
Shot, and 8.0 Mega Pixels). The generated PCR product size
using these primers is 640 bp. This PCR product was digested
with NcoI at 65 C (Fermentas, Canada), the Arg16 allele is
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allele is distinguished by two bands at 306 and 334 bp.
2.3. Statistical analysis
The results were analyzed using the Statistical Package of So-
cial Sciences (SPSS) computer software program, version 16.0
(Chicago, IL, USA). Data are presented as numbers and per-
centages. Association between categorical groups was evalu-
ated using Chi-square (v2) test; we also calculated odd ratio
(OR) and 95% conﬁdence interval (CI). A P-value less than
0.05 was considered statistically signiﬁcant while, P value of
<0.001 indicates a high signiﬁcant result.
For inclusion in the study, an informed written consent was
obtained from the children’s guardians. The study protocol
was approved by the hospital’s ethical committee.
3. Results
Results are summarized in Tables 1 and 2. There was a highly
statistically signiﬁcant difference of polymorphisms’ distribu-
tion of b2AR gene at codon 16 among asthmatic patients
and control subjects (v2 = 11.904; P= 0.0026), also among
severe asthmatics and mild/moderate asthmatics
(v2 = 10.108; P = 0.0064). We found also highly statistically
signiﬁcant difference of distribution of heterozygous Arg16Gly
among all asthmatics and controls (v2 = 7.585; P= 0.0059)
and also between severe and mild/moderate asthma
(v2 = 8.182; P= 0.0042, Table 1).
3.1. Heterozygous Arg16Gly genotype of b2AR gene
There was a higher frequency of heterozygous Arg16Gly of
b2AR in asthmatic children than in normal healthy controls
(45% vs. 5.3%, P< 0.001), with odd ratio (OR) 14.727
(95% conﬁdence interval (CI): 1.789–121.209). Statistical anal-
ysis showed the presence of strong association of heterozygous
Arg16Gly of b2AR with severe asthmatics rather than that in
control subjects (70% vs. 5.3%, P< 0.001), with odd ratio
(OR) 42 (95% conﬁdence interval (CI): 4.520–390.297). Also,
there was association between heterozygous Arg16Gly with se-
vere asthma when compared to mild/moderate asthmatics
(OR, 9.333; 95% CI: 2.179–39.962, P< 0.05). Moreover, theTable 1 Distribution and comparison of b2AR genotypes at codon
Genotype Homozygous Arg Heterozyg
No. % No.
Control (n = 19) 10 52.6 1
All asthmatics (n= 40) 7 17.5 18
v2 6.133 7.585 0.00284
P value 0.0133* 0.0059** 0.9575
Severe asthma (n= 20) 2 10 14
Mild/moderate asthma (n= 20) 5 25 4
v2 0.693 8.182 3.840
P value 0.4053 0.0042** 0.0501*
P value >0.05 (non signiﬁcant).
* P value <0.05 (signiﬁcant).
** P value <0.001 (highly signiﬁcant).highest OR in heterozygous Arg16Gly (42) in comparing se-
vere asthmatic children with controls suggests a dominant
mode of action of the heterozygous Arg16Gly in development
of asthma severity (Table 2). This indicates also that heterozy-
gous Arg16Gly of b2AR has a high dependent risk factor for
the pathogenesis of asthma and has a strong association with
severe asthma.
3.2. Homozygous Gly16 genotype of b2AR gene
Homozygous Gly16 has a signiﬁcant difference between severe
and mild to moderate asthma (20% vs. 55%, v2 = 3.84,
P= 0.05). Odd ratio revealed that homozygous Gly plays as
a protective factor when comparing severe to mild/moderate
asthmatics (OR, 0.205; 95% CI: 0.050–0.834, P< 0.05).
Moreover, there was a higher frequency of homozygous
Gly16 in control subjects than that in asthmatic children
(42.1% vs. 37.5%; P> 0.05), with odd ratio (OR) 0.825
(95% conﬁdence interval (CI): 0.271–2.511), with no signiﬁ-
cant deference. But OR revealed that homozygous Gly has
low independent risk factor when comparing mild/moderate
asthmatics to their controls (OR, 1.681; 95% CI: 0.473–
5.967) (Table 2).
3.3. Homozygous Arg16 genotype of b2AR gene
On the other hand, there was higher prevalence of homozy-
gous Arg16 genotype in normal healthy controls than that in
asthmatics (52.6% vs. 17.5%; P< 0.05), with odd ratio
(OR) 0.191 (95% conﬁdence interval (CI): 0.057–0.643), which
revealed that homozygous Arg16 may be considered as a reces-
sive protective factor for the pathogenesis of asthma in chil-
dren (Table 2).
4. Discussion
The frequencies of b2AR genotypes at position 16 in the hu-
man population, was 15–20% for homozygous Arginine,
45% for homozygous Glycine and 38% for heterozygous
genotype [19]. However there was a marked interethnic differ-
ence in the frequency of b2AR polymorphisms among the eth-
nic healthy group for example the Gly16 allele was more
frequent in Caucasian–Americans 54.3% vs. 41.3% in16 in all studied groups.
ous Arg16Gly Homozygous Gly Chi-square
% No. % v2 P value
5.3 8 42.1 11.904 0.0026**
45 15 37.5
70 4 20 10.108 0.0064**
20 11 55
Table 2 Frequency of b2AR genotypes at codon 16 in all studied groups.
Homozygous Arg Heterozygous Arg16Gly Homozygous Gly
Controls (n= 19); n (%) 10 52.6% 1 5.3% 8 42.1%
All asthmatics (n= 40; n (%) (vs. controls) 7 17.5% 18 45% 15 37.5%
Odds ratio 0.191 14.727 0.825
95% CI 0.057–0.643 1.789–121.209 0.271–2.511
P value <0.05* <0.001** >0.05
Mild/moderate asthma (n= 20; n (%) (vs. controls) 5 25% 4 20% 11 55%
Odds ratio 0.300 4.5 1.681
95% CI 0.077–1.163 0.455–44.546 0.473–5.967
P value >0.05 >0.05 >0.05
Severe asthma (n= 20; n (%) (vs. controls) 2 10% 14 70% 4 20%
Odds ratio 0.100 42.000 0.344
95% CI 0.018–0.556 4.520–390.297 0.083–1.429
P value <0.05* <0.001** >0.05
Severe asthma (vs. mild/moderate)
Odds ratio 0.333 9.333 0.205
95% CI 0.056–1.971 2.179–39.962 0.050–0.834
P value >0.05 <0.05* <0.05*
By Fisher exact test P value >0.05 (non signiﬁcant).
* By Fisher exact test P value <0.05 (signiﬁcant).
** By Fisher exact test P value <0.001 (highly signiﬁcant).
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lele was more frequent 57% than Gly16 allele 43% [21]. In
the current study we found the frequencies of b2AR genotypes
at position 16 among Egyptian children, was 52.6% for homo-
zygous Arg16, 5.3% for heterozygous Arg16Gly and 42.1%
for homozygous Gly16. Such ethnic geographic differences
may explain alterations in the response to b2AR agonists in
different ethnic groups.
In this study, there was a signiﬁcant difference of distribution
of b2AR genotypes at codon 16 among all asthmatics and their
control subjects, and also among severe and mild/moderate
asthmatics, where the heterozygous Arg16Gly genotype was
found to have a higher frequency among patients with severe
asthma vs. controls and also among patients with severe asthma
vs. those with mild/moderate asthma. This was conﬁrmed by
Reihsaus et al. and McQuitty et al. [18,22] who demonstrated
that the Arginine16/Glycine form of the receptor is associated
with nocturnal falls in peak ﬂow rate in subjects with asthma
[23] and with increased airway reactivity [24]. Also, Weir et al.
[25] demonstrated thatGly16/Glu27 haplotypewasmore preva-
lent in severe than in mild asthmatics and these patients that
could be at increased risk of fatal or near fatal asthma. Thak-
kinstian et al. [26] also suggested that the risk of asthma is mod-
iﬁed by the allele at position 16, and Wang et al. [27] found that
both in utero and childhood exposure to tobacco smoke were
associated with an increased risk for wheeze in children, and
the risks were greater for children with the Arginine16/Glycine
phenotype. The same result was also reported in other ethnic
groups as the Anglosaxic countries and the fareast [28,29] as
they found it to be increased in asthma patients whowere admit-
ted for asthmatic attacks [30] or corticosteroid dependent [18] or
have nocturnal asthma [22].
So, in this study we demonstrated that heterozygous Arg16-
Gly of b2AR gene has probably dominant mode of action in
development of asthma severity. Thus, we suggest that this
genotype of b2AR could be a predictor of the pathogenesis
of asthma and has strong association with severe asthma. Thiswas in agreement with Litonjua [14] who reported that hetero-
zygous Arg16Gly has associations with other asthma-related
phenotypes, such as nocturnal asthma and asthma severity.
Homozygous Gly16 genotype showed a signiﬁcant differ-
ence between severe and mild to moderate asthma. But OR re-
vealed that homozygous Gly16 plays as a protective factor
when comparing severe to mild/moderate asthmatics (OR,
0.205; 95% CI: 0.050–0.834, P< 0.05). This result was in
agreement with Thakkinstian et al. [26] who suggested that
homozygous Gly16 has a recessive protective effect for asth-
matic children. Also, we found the absence of a signiﬁcant def-
erence between the asthmatics who had Gly16 homozygous of
b2AR and that in control subjects, and odd ratio revealed that
homozygous Gly was low independent risk factor when com-
pared mild/moderate asthmatics to their controls (OR, 1.681;
95% CI: 0.473–5.967) (Table 2). This result was in accordance
with Reishause et al. [18] who found no correlation between
Gly16 homozygosity and hospital admissions, indicating that
mutations of b2AR are not a primary cause of asthma and
Wier et al. [25] found no increase in frequency of Gly16 in fatal
or no fatal asthma. Also, Schachor et al. [31] demonstrated ab-
sence of a signiﬁcant difference between the distribution of
Gly16 in asthmatic subjects and their controls, i.e., no signiﬁ-
cant impact of b2AR polymorphisms on asthma severity in
Ashkenazi Jews, non-Ashkenazi Jews or Arabs. Pagaria [32]
found that b2AR polymorphisms are not strongly associated
with asthma incidence or prevalence. Also, Gao et al. [33] re-
ported that Gly16 homozygous of b2AR was low independent
risk factor for the pathogenesis of asthma.
Howevermany literatures have contradictory results. Conto-
poulos et al. [34] found thatGly16 homozygotes hadmuch high-
er risk factor for asthma severity. Also, many authors Yin et al.
[35] Shigemitsu and Afshar [36] reported that Gly16 polymor-
phism of b2AR was overrepresented in nocturnal asthmatic pa-
tients, and correlated with asthma severity [16].
In the current study, we found that homozygous Arg16 has
a protective role in Egyptian children. This was in agreement
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the risk of hospital admission caused by asthma exacerbations
in the children with the Arg/Arg16 genotype. The Arg16 vari-
ant did not appear to be associated with general asthma sever-
ity because there was no difference in the Arg16 allele
frequency across the different treatment steps. The Arg16 var-
iant had no signiﬁcant effects on measures of pulmonary func-
tion. Also, Summerhill et al. [38] reported that the Arg/Arg-16
children with asthma may constitute a signiﬁcant population
that is likely to show better asthma control and they suggested
that the b2AR Arg16Arg polymorphism inﬂuences either lung
growth or the rate of decline of lung function with age.
The cause of the various effect of this polymorphism in var-
ious geographic regions still remains to be determined and it is
possible that the balance between the various pathogenic fac-
tors that determine the severity of asthma differs in various re-
gions [31].
5. Conclusion
Our study demonstrated a signiﬁcant association of heterozy-
gous Arg16Gly and severe asthma. Even in studies which dem-
onstrated that polymorphisms of b2AR are not important risk
factors for development of asthma, meta-analyses on the ef-
fects of this polymorphism suggested associations with other
asthma-related phenotypes, such as nocturnal asthma and
asthma severity [33].
6. Recommendation
Future studies need to fully characterize all of the variations in
the b2AR gene and perform comprehensive association studies
and the further progress in asthma care will require better
understanding of the molecular and genetic basis for the clin-
ical heterogeneity seen in this disorder. Also, the relation be-
tween acute and chronic inﬂammation as well as airway
hyper-responsiveness and airway remodeling is still unclear.
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